Clinical Pharmacology & Biopharmaceutics
Open Access

Parasar Pal

Biostatistical Sciences, IDFR, Novartis Healthcare Pvt Ltd, Hyderabad, Telangana, India

Biography

Dr. Parasar Pal has obtained Doctor of Philosophy from University of Kalyani, West Bengal in Business Administration. Prior to that he completed Masters in Statistics from University of Calcutta. He has more than fourteen years of experience in providing statistical support to various early development clinical trials including Proof of Concept and Pharmacodynamics. He provided project level statistical support to some key products during submission. He also worked in late phase clinical trial and provided statistical support in one of the Neuroscience projects.

Publications

Assessment of Drug Interaction Potential between LCZ696, an Angiotensin Receptor Neprilysin Inhibitor, and Digoxin or Warfa rin

LCZ696 (sacubitril/valsartan) is a first-in-class angiotensin receptor neprilysin inhibitor that simultaneously inhibits neprilysin and blocks the angiotensin II receptor. LCZ696 has been recently approved for treatment of HF and likely be co-administered with digoxin or warfarin. The drug interaction potential between LCZ696 and digoxin or warfari... Read More»

Surya Ayalasomayajula, Pierre Jordaan, Parasar Pal, Priyamvada Chandra, Diego Albrecht, Thomas Langenickel, Iris Rajman and Gangadhar Sunkara

Research Article: Clin Pharmacol Biopharm 2015, 4:147

DOI: 10.4172/2167-065X.1000147

Abstract Peer-reviewed Full Article Peer-reviewed Article PDF